Samsung Bioepis, maker of Imraldi, has developed an autoinjector device that aims to address some of the mobility limitations that patients with rheumatoid arthritis may have in self-administering their adalimumab with a syringe.
A study published today in Drug Design, Development and Therapy investigated the pharmacokinetics (PK), safety, and tolerability of SB5, an adalimumab biosimilar sold in the European Union as Imraldi, administered via autoinjector (AI) versus a prefilled syringe (PFS), and found that the 2 administration methods were similar.
Samsung Bioepis, maker of Imraldi, has developed an AI device that aims to address some of the mobility limitations that patients with rheumatoid arthritis (RA) may have in self-administering their adalimumab with a PFS. The AI contains the same dose of the biosimilar as the PFS, and incorporates an ergonomic design and a safety feature to prevent needle-stick injuries.
In a phase 1, randomized, open-label, single-dose, parallel-group study conducted at 1 site in Belgium and 1 site in New Zealand, 109 healthy volunteers were randomized 1:1 to receive a dose of 40 mg of adalimumab by AI or PFS and were observed for 57 days.
The PK population included 94 subjects in each group. The mean serum concentration-time profiles were superimposable between the groups, and the mean values of PK parameters were similar. The 90% confidence intervals for the geometric least squares mean ratios of AUCinf, AUClast, and Cmax ranged from 0.9503 to 1.2240, and fell within the predefined equivalence margin of 0.8 to 1.25.
The safety group included 95 subjects in the AI group and 94 subjects from the PFS group. The percentage of subjects who had treatment-emergent adverse events (TEAEs) was similar between groups, with 68.4% of the AI group and 60.6% of the PFS group having a TEAE, and with upper respiratory tract infection the most commonly reported. Few local injection site reactions (ISRs) were observed in either group, and most were mild. The most frequently reported ISR was redness on day 1.
The authors concluded that, in healthy volunteers who received single doses of Imraldi, the AI and PFS demonstrated similar PK, safety, and injection site assessments. These results suggest that there would be no clinical differences between the 2 administration methods in terms of safety and efficacy, and that the AI represents an alternative delivery option to the PFS.
Reference
Shin D, Lee Y, Jeong D, Ellis-Pegler R. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects. Drug Des Devel Ther. 2018;12:3799-3805. doi: 10.2147/DDDT.S169082.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.